SCA
ITCI

Secor Capital Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Secor Capital Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-31,004
Closed -$378K – 280
2019
Q1 		$378K Buy
31,004
+4,560
+17% +$58.3K 0.08% 303
2018
Q4 		$301K Sell
26,444
-41,812
-61% -$675K 0.04% 373
2018
Q3 		$1.48M Buy
+68,256
New +$1.43M 0.16% 192
2018
Q1 		– Sell
-57,628
Closed -$834K – 661
2017
Q4 		$834K Buy
+57,628
New +$890K 0.03% 308
2016
Q4 		– Sell
-28,657
Closed -$437K – 639
2016
Q3 		$437K Buy
+28,657
New +$1.16M 0.05% 382

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Secor Capital Advisors's ITCI Position: Q2 2019 in Review

Secor Capital Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2019, closing a stake of 31,004 shares — an estimated $378K sold.

Secor Capital Advisors first reported a position in ITCI in Q3 2016 and held it in 5 quarters. The position peaked at $1.48M in Q3 2018. 126 funds tracked by Wall St. Rank hold ITCI as of Q2 2019.

  • Secor Capital Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 31,004 Intra-Cellular Therapies Inc. shares in Q2 2019, an estimated $378K.
  • Secor Capital Advisors first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 5 quarters.
  • Secor Capital Advisors's Intra-Cellular Therapies Inc. position peaked at $1.48M in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2019.

Based on Secor Capital Advisors's 13F filing for Q2 2019.